Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial.

Sandro BarniGerardo RosatiSara LonardiNicoletta PellaMaria BanziMaria G ZampinoKatia F DottiLorenza RimassaPaolo MarchettiEvaristo MaielloFabrizio ArtioliDaris FerrariRoberto LabiancaPaolo BidoliAlberto ZaniboniAlberto SobreroVincenzo IaffaioliSabino De PlacidoGian Luca FrassinetiAndrea CiarloAngela BuonadonnaNicola SilvestrisElena PiazzaLorenzo PavesiMauro MoroniMario ClericoMassimo AgliettaPaolo GiordaniFrancesca GalliFabio GalliFausto Petrelli

Published in: Therapeutic advances in medical oncology (2020)

The use of the KS did not predict VTEs in a low-moderate thromboembolic risk population as CRC. These data did not support the use of KS to predict VTE during adjuvant chemotherapy, and suggest that other risk assessment models should be researched.

Keyphrases

risk assessment
venous thromboembolism
atrial fibrillation
early stage
clinical trial
high intensity
human health
phase iii
heavy metals
machine learning
phase ii
climate change
open label